Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats. 2008

Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
Department of Veterans Affairs, Nebraska Western Iowa Health Care System, Omaha, NE 68105, USA. roger.reidelberger@va.gov

Chronic administration of anorexigenic substances to experimental animals by injections or continuous infusion typically produces either no effect or a transient reduction in food intake and body weight. Our aim here was to identify an intermittent dosing strategy for intraperitoneal infusion of peptide YY(3-36) [PYY(3-36)] that produces a sustained reduction in daily food intake and adiposity in diet-induced obese rats. Rats (665+/-10 g body wt, 166+/-7 g body fat) with intraperitoneal catheters tethered to infusion swivels had free access to a high-fat diet. Vehicle-treated rats (n=23) had relatively stable food intake, body weight, and adiposity during the 9-wk test period. None of 15 PYY(3-36) dosing regimens administered in succession to a second group of rats (n=22) produced a sustained 15-25% reduction in daily food intake for >5 days, although body weight and adiposity were reduced across the 9-wk period by 12% (594+/-15 vs. 672+/-15 g) and 43% (96+/-7 vs. 169+/-9 g), respectively. The declining inhibitory effect of PYY(3-36) on daily food intake when the interinfusion interval was >or=3 h appeared to be due in part to an increase in food intake between infusions. The declining inhibitory effect of PYY(3-36) on daily food intake when the interinfusion interval was <3 h suggested possible receptor downregulation and tolerance to frequent PYY(3-36) administration; however, food intake significantly increased when PYY(3-36) treatments were discontinued for 1 day following apparent loss in treatment efficacies. Together, these results demonstrate the development of a potent homeostatic response to increase food intake when PYY(3-36) reduces food intake and energy reserves in diet-induced obese rats.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D004041 Dietary Fats Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados. Fats, Dietary,Dietary Fat,Fat, Dietary
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D006706 Homeostasis The processes whereby the internal environment of an organism tends to remain balanced and stable. Autoregulation

Related Publications

Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
October 2007, Brain research,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
November 2005, Diabetes,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
May 2015, Endocrinology,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
January 2013, Obesity surgery,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
October 2004, Obesity research,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
July 2007, American journal of physiology. Regulatory, integrative and comparative physiology,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
September 2005, Endocrinology,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
May 2011, Diabetes, obesity & metabolism,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
January 2011, Journal of toxicology and environmental health. Part A,
Roger D Reidelberger, and Alvin C Haver, and Prasanth K Chelikani, and James L Buescher
February 2001, FEBS letters,
Copied contents to your clipboard!